山帕曲拉
| 中文名称 | 山帕曲拉 |
|---|---|
| 中文同义词 | 山帕曲拉;化合物 T16840 |
| 英文名称 | sampatrilat |
| 英文同义词 | sampatrilat;UK-81252;L-Tyrosine, N2-(methylsulfonyl)-L-lysyl-1-[(2S)-3-amino-2-carboxypropyl]cyclopentanecarbonyl- |
| CAS号 | 129981-36-8 |
| 分子式 | C26H40N4O9S |
| 分子量 | 584.687 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 129981-36-8.mol |
| 结构式 |  |
山帕曲拉 性质
| 形态 | 固体 |
|---|---|
| 颜色 | 白色至米白色 |
Sampatrilat (UK-81252) 是一种强效具有口服活性的血管肽酶抑制剂，可抑制血管紧张素转换酶 (ACE) 和中性血管内肽酶 (NEP)。Sampatrilat 对 C-domain ACE (Ki=13.8 nM) 的抑制作用是 N-domain 的 12.4 倍 (Ki=171.9 nM)。Sampatrilat (UK-81252) 可用于慢性心力衰竭和血压调节的相关研究。
Ki: 13.8 nM (cACE); 171.9 nM (nACE)
Sampatrilat (oral adminstration; 30 mg/kg; once a day; 5 weeks) reduces the mortality of the rats with CAL (20% versus 57% for untreated rats) and increase in the survival rate and improvement of hemodynamic function of the rats with CAL. This compound suppresses tissue ACE and neutral endopeptidase (NEP) activities, but it does not affect the arterial blood pressure, whereas it attenuates the CAL-induced increases in the left ventricular end-diastolic pressure, heart weight, and collagen content of the viable left Ventricle.
| Animal Model: | Left coronary artery ligation (CAL) and sham-operated rats |
| Dosage: | 30 mg/kg |
| Administration: | Oral adminstration |
| Result: | Prevented the increases in heart weight and cardiac collagen content of the rats with CAL. |